Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
| 0.9476 | |
| 0.94 | |
| - | |
| 0.9695 | |
| 0.94 | |
| 0.69-1.6 | |
| 55 477 K | |
| 60 295 K | |
| 8 412 K | |
| -0.27 | |
| 1.879 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Kronos Bio, Inc. Company eliminates three executive officer roles and appoints new Executive Leadership team SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, In...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mone...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
